Companies › Arcus Biosciences
7 active drug programs in 20 registered trials: 9 Phase 2, 9 Phase 1, 2 Phase 3; Oncology, Gastroenterology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| casdatifan Adenosine A2A receptor antagonist | ADORA2A | Phase 3 | Metastatic Clear Cell Renal Cell Carcinoma; Healthy Participants; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma … | May 2027 |
| Quemliclustat CD73 inhibitor | NT5E | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma; Gastrointestinal Tract Malignancies; Oligometastatic Prostate Cancer; Biliary Tract Carcinoma … | Nov 2030 |
| zimberelimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 2 | Gastrointestinal Tract Malignancies; Non Small Cell Lung Cancer; Advanced Cancer; Clear Cell Renal Cell Carcinoma | Sep 2027 |
| Domvanalimab T-cell immunoreceptor with Ig and ITIM domains inhibitor | TIGIT | Phase 2 | Gastrointestinal Tract Malignancies; Non Small Cell Lung Cancer | – |
| AB102 | – | Phase 1 | Healthy Volunteers | Dec 2026 |
| AB598 | – | Phase 1 | Advanced Cancer | Sep 2027 |
| AB801 Adenosine A2A receptor antagonist | – | Phase 1 | Advanced Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06120075 | AB801 | Phase 1 | Advanced Cancer | Oncology | Apr 2026 |
| NCT05329766 | Quemliclustat | Phase 2 | Gastrointestinal Tract Malignancies | Oncology | Sep 2026 |
| NCT05329766 | zimberelimab | Phase 2 | Gastrointestinal Tract Malignancies | Oncology | Sep 2026 |
| NCT05329766 | Domvanalimab | Phase 2 | Gastrointestinal Tract Malignancies | Oncology | Sep 2026 |
| NCT04736173 | zimberelimab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Sep 2026 |
| NCT04736173 | Domvanalimab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Sep 2026 |
| NCT05915442 | Quemliclustat | Phase 2 | Oligometastatic Prostate Cancer | Oncology | Dec 2026 |
| NCT06048133 | Quemliclustat | Phase 2 | Biliary Tract Carcinoma | Oncology | Dec 2026 |
| NCT07662057 | AB102 | Phase 1 | Healthy Volunteers | Other | Dec 2026 |
| NCT06048484 | Quemliclustat | Phase 2 | Pancreatic Ductal Adenocarcinoma | Oncology | Apr 2027 |
| NCT07751250 | casdatifan | Phase 1 | Healthy Participants | Gastroenterology | May 2027 |
| NCT05891171 | zimberelimab | Phase 1 | Advanced Cancer | Oncology | Sep 2027 |
| NCT05891171 | AB598 | Phase 1 | Advanced Cancer | Oncology | Sep 2027 |
| NCT07397611 | casdatifan | Phase 2 | Renal Cell Carcinoma | Oncology | Jan 2028 |
| NCT07011719 | casdatifan | Phase 3 | Metastatic Clear Cell Renal Cell Carcinoma | Oncology | Apr 2028 |
| NCT05536141 | casdatifan | Phase 1 | Clear Cell Renal Cell Carcinoma | Oncology | Mar 2029 |
| NCT05536141 | zimberelimab | Phase 1 | Clear Cell Renal Cell Carcinoma | Oncology | Mar 2029 |
| NCT07667335 | Quemliclustat | Phase 1 | Locally Advanced Bladder Urothelial Carcinoma | Oncology | Jul 2029 |
| NCT07748988 | casdatifan | Phase 1 | Refractory Clear Cell Renal Cell Carcinoma | Oncology | Jul 2030 |
| NCT06608927 | Quemliclustat | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma | Oncology | Nov 2030 |
Cash and short-term investments of $630m on 2026-09-30; operating cash outflow about $463m a year; runway about 16 months at that burn, to Feb 2028; 4 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Kura Oncology Eikon Therapeutics ALX Oncology CSPC Megalith Biopharmaceutical Chipscreen Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.